ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
48 announcements
KIMS delivered strong revenue growth led by Kondapur's rapid ramp-up, despite temporary margin compression from new oncology programs.
KIMS's CARE Ratings monitoring report shows ₹1,311.81 crore of the ₹1,476.45 crore QIP proceeds utilised till Q2 FY27. No deviation from the stated objects was reported.
KIMS re-appointed Dr. Abhinay Bollineni as Director & CEO, Dr. Bhaskara Rao Bollineni as CMD, and Ms. Dandamudi Anitha as Whole-time Director. Terms start in 2027.
Q2 FY27 total revenue Rs13,630 Mn (+41.3% YoY), EBITDA Rs2,789 Mn (20.5% margin), PAT Rs757 Mn (+5.1% YoY). Expansion via 700+ beds planned.
KIMS reported Q2 FY27 consolidated revenue of Rs 1,363 Crore, up 41.3% YoY, with PAT of Rs 76 Crore. EBITDA rose 34% YoY to Rs 279 Crore.
Krishna Institute of Medical Sciences Ltd reported revenue from operations of ₹1,344 Cr (+39.9% YoY) and net profit of ₹74.6 Cr (+3.6% YoY) for Q2 FY27.
KIMS Saveera Hospital in Anantapur expanded from 250 to 500 beds, with new oncology and mother-and-child blocks inaugurated November 1, 2026. No monetary value disclosed.
KIMS acquired a 5.82% stake in Ushahkal Abhinav Specialty Hospital LLP for Rs.15 Crore via primary infusion. The Sangli hospital reported FY26 turnover of Rs.80.42 Crore.
KIMS Ltd acquired a 51% stake in Sarvottam Health Care Private Limited for up to ₹79.50 Crore, aiming to expand its healthcare operations in Kakinada.
KIMS discloses a pending suit over its Chennai hospital land lease, naming it defendant. Supreme Court dismissed its SLP; no injunction halts the project.
KIMS Ltd informed exchanges of a Board Meeting on November 4, 2026 to approve Q2 and H1 unaudited results. Trading window closes until 48 hours post-disclosure.
The company filed its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulations.
KIMS provided additional information regarding the board meeting held on October 06, 2026, in response to a BSE query.
KIMS will acquire a 51% stake in Insignia Healthcare Private Limited for ₹75 Crore as a strategic investment. This will occur in tranches over 24 months.
KIMS will acquire a 22% equity stake in Splendid Hospitals Private Limited for up to ₹40 Crore. This strategic investment will be executed via primary infusion.
KIMS will acquire a 51% stake in Sarvottam Health Care Private Limited for up to ₹80.00 Crore.
KIMS Hospitals will acquire a 6% stake in Ushahkal Abhinav Specialty Hospital LLP for ₹15 Crore as a strategic investment to enhance operational efficiency.
KIMS will acquire up to a 51% equity stake in Insignia Healthcare Private Limited. The acquisition represents a strategic investment in the healthcare sector.
Promoters pledged 2,80,08,979 equity shares (6.66%) to Catalyst Trusteeship as debenture trustee. The pledge secures existing debenture obligations with no new capital involved.
Krishna Institute of Medical Sciences Ltd entered an Operations and Management Agreement with Sarvottam Health Care Pvt Ltd for 5+5 years to manage their operations.
KIMS Hospitals held its 24th Annual General Meeting on August 27, 2026. The meeting discussed financial statements and various ordinary and special business items.
KIMS has clarified that the news report claiming a $52 million acquisition of Renova Hospitals is false. The company confirms no such discussions or agreements exist.
KIMS entered into an Operations and Management Agreement and Call Option Agreement with Aurevia Hospitals to manage Arete Hospitals for an initial five-year term.
KIMS has entered into an Operations and Management Agreement to manage Arete Hospitals, Hyderabad, for an initial 5-year term. It also secured an acquisition call option.
KIMS allotted 77,02,182 warrants on a preferential basis to promoters. The company received Rs. 149.99999 Crore as 25% subscription money for these warrants.
KIMS Hospitals has received in-principle approval from BSE and NSE to issue 77,02,182 warrants to promoters on a preferential basis.
KIMS Hospitals submitted its Integrated Annual Report for FY 2025-26 to the stock exchanges. The document is available on the company's website for shareholders.
Krishna Institute of Medical Sciences Limited will hold its 24th Annual General Meeting on August 27, 2026, via video conferencing.
KIMS delivered strong EBITDA margins despite lower ARPOB compared to peers, driven by lean operational efficiency and high patient volumes.
Krishna Institute of Medical Sciences Limited filed its Monitoring Agency Report for the quarter ended June 30, 2026, confirming no material deviations in QIP proceeds utilization.